177 related articles for article (PubMed ID: 37322295)
1. A clinicopathological analysis of supratentorial ependymoma, ZFTA fusion-positive: utility of immunohistochemical detection of CDKN2A alterations and characteristics of the immune microenvironment.
Hashimoto N; Suzuki T; Ishizawa K; Nobusawa S; Yokoo H; Nishikawa R; Yasuda M; Sasaki A
Brain Tumor Pathol; 2023 Jul; 40(3):163-175. PubMed ID: 37322295
[TBL] [Abstract][Full Text] [Related]
2. Molecular subgrouping of ependymoma across three anatomic sites and their prognostic implications.
Chinnam D; Gupta K; Kiran T; Saraswati A; Salunke P; Madan R; Kumar N; Radotra BD
Brain Tumor Pathol; 2022 Jul; 39(3):151-161. PubMed ID: 35348910
[TBL] [Abstract][Full Text] [Related]
3. Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions.
Tauziède-Espariat A; Siegfried A; Nicaise Y; Kergrohen T; Sievers P; Vasiljevic A; Roux A; Dezamis E; Benevello C; Machet MC; Michalak S; Puiseux C; Llamas-Gutierrez F; Leblond P; Bourdeaut F; Grill J; Dufour C; Guerrini-Rousseau L; Abbou S; Dangouloff-Ros V; Boddaert N; Saffroy R; Hasty L; Wahler E; Pagès M; Andreiuolo F; Lechapt E; Chrétien F; Blauwblomme T; Beccaria K; Pallud J; Puget S; Uro-Coste E; Varlet P;
Acta Neuropathol Commun; 2021 Aug; 9(1):135. PubMed ID: 34389065
[TBL] [Abstract][Full Text] [Related]
4. MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma.
Nowak J; Jünger ST; Huflage H; Seidel C; Hohm A; Vandergrift LA; von Hoff K; Rutkowski S; Pietsch T; Warmuth-Metz M
Clin Neuroradiol; 2019 Dec; 29(4):595-604. PubMed ID: 30027327
[TBL] [Abstract][Full Text] [Related]
5. Adult intracranial ependymoma-relevance of DNA methylation profiling for diagnosis, prognosis, and treatment.
Träger M; Schweizer L; Pérez E; Schmid S; Hain EG; Dittmayer C; Onken J; Fukuoka K; Ichimura K; Schüller U; Dührsen L; Müther M; Paulus W; Thomas C; Gutt-Will M; Schucht P; Maragkou T; Schittenhelm J; Eckert F; Niyazi M; Fleischmann DF; Dorostkar MM; Feyer P; May SA; Moskopp D; Badakhshi H; Radke C; Walter J; Ehret F; Capper D; Kaul D
Neuro Oncol; 2023 Jul; 25(7):1286-1298. PubMed ID: 36734226
[TBL] [Abstract][Full Text] [Related]
6. Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study.
Chapman RJ; Ghasemi DR; Andreiuolo F; Zschernack V; Espariat AT; Buttarelli FR; Giangaspero F; Grill J; Haberler C; Paine SML; Scott I; Jacques TS; Sill M; Pfister S; Kilday JP; Leblond P; Massimino M; Witt H; Modena P; Varlet P; Pietsch T; Grundy RG; Pajtler KW; Ritzmann TA
Neuro Oncol; 2023 Oct; 25(10):1871-1882. PubMed ID: 36916248
[TBL] [Abstract][Full Text] [Related]
7. epi-Aszonalenin B from Aspergillus novofumigatus inhibits NF-κB activity induced by ZFTA-RELA fusion protein that drives ependymoma.
Ishikawa K; Ishii M; Yaguchi T; Katada T; Ichinose K; Ohata S
Biochem Biophys Res Commun; 2022 Mar; 596():104-110. PubMed ID: 35131506
[TBL] [Abstract][Full Text] [Related]
8. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
Satomi K; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Narita Y; Ichimura K; Yoshida A
Mod Pathol; 2021 Apr; 34(4):688-700. PubMed ID: 33077924
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas.
Maragkou T; Reinhard S; Jungo P; Pasquier B; Neuenschwander M; Schucht P; Vassella E; Hewer E
Pathology; 2023 Jun; 55(4):466-477. PubMed ID: 37032198
[TBL] [Abstract][Full Text] [Related]
10. p16 Immunohistochemistry as a Screening Tool for Homozygous CDKN2A Deletions in CNS Tumors.
Zschernack V; Andreiuolo F; Dörner E; Wiedey A; Jünger ST; Friker LL; Maruccia R; Pietsch T
Am J Surg Pathol; 2024 Jan; 48(1):46-53. PubMed ID: 37947008
[TBL] [Abstract][Full Text] [Related]
11. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.
Witt DA; Donson AM; Amani V; Moreira DC; Sanford B; Hoffman LM; Handler MH; Levy JMM; Jones KL; Nellan A; Foreman NK; Griesinger AM
Pediatr Blood Cancer; 2018 May; 65(5):e26960. PubMed ID: 29350470
[TBL] [Abstract][Full Text] [Related]
12. Ependymoma associated protein Zfta is expressed in immature ependymal cells but is not essential for ependymal development in mice.
Herranz-Pérez V; Nakatani J; Ishii M; Katada T; García-Verdugo JM; Ohata S
Sci Rep; 2022 Jan; 12(1):1493. PubMed ID: 35087169
[TBL] [Abstract][Full Text] [Related]
13. Strong OLIG2 expression in supratentorial ependymoma, ZFTA fusion-positive: A potential diagnostic pitfall.
de Castro JVA; Kulikowski LD; Wolff BM; Natalino R; Carraro DM; Torrezan GT; Scapulatempo Neto C; Amancio CT; Canedo FSNA; Feher O; Costa FD
Neuropathology; 2024 Apr; 44(2):167-172. PubMed ID: 37855183
[TBL] [Abstract][Full Text] [Related]
14. Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas.
Zheng T; Ghasemi DR; Okonechnikov K; Korshunov A; Sill M; Maass KK; Benites Goncalves da Silva P; Ryzhova M; Gojo J; Stichel D; Arabzade A; Kupp R; Benzel J; Taya S; Adachi T; Shiraishi R; Gerber NU; Sturm D; Ecker J; Sievers P; Selt F; Chapman R; Haberler C; Figarella-Branger D; Reifenberger G; Fleischhack G; Rutkowski S; Donson AM; Ramaswamy V; Capper D; Ellison DW; Herold-Mende CC; Schüller U; Brandner S; Driever PH; Kros JM; Snuderl M; Milde T; Grundy RG; Hoshino M; Mack SC; Gilbertson RJ; Jones DTW; Kool M; von Deimling A; Pfister SM; Sahm F; Kawauchi D; Pajtler KW
Cancer Discov; 2021 Sep; 11(9):2230-2247. PubMed ID: 33879448
[TBL] [Abstract][Full Text] [Related]
15. CDKN2A/p16 in ependymomas.
Bortolotto S; Chiadò-Piat L; Cavalla P; Bosone I; Mauro A; Schiffer D
J Neurooncol; 2001 Aug; 54(1):9-13. PubMed ID: 11763427
[TBL] [Abstract][Full Text] [Related]
16. Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas.
Pohl LC; Leitheiser M; Obrecht D; Schweizer L; Wefers AK; Eckhardt A; Raffeld M; Sturm D; Pajtler KW; Rutkowski S; Fukuoka K; Ichimura K; Bockmayr M; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):24. PubMed ID: 38265522
[TBL] [Abstract][Full Text] [Related]
17. Correlation of MTAP immunohistochemical deficiency with CDKN2A homozygous deletion and clinicopathological features in pleomorphic xanthoastrocytoma.
Lou L; Li J; Qin M; Tian X; Guo W; Li Y
Brain Tumor Pathol; 2023 Jan; 40(1):15-25. PubMed ID: 36550382
[TBL] [Abstract][Full Text] [Related]
18. ZFTA (Zinc Finger Translocation Associated) Fusion in Supratentorial Ependymomas: Low Prevalence in South Asians and No Correlation with Survival.
Goyal-Honavar A; Balasundaram A; Thayakaran IP; Babu M; Pai R; Joseph J; Jayachandran R; Chacko AG; Mathew LG; Balakrishnan R; Rajshekhar V; Jeyaseelan L; Sudarsanam TD; Chacko G
World Neurosurg; 2022 Aug; 164():e82-e90. PubMed ID: 35378317
[TBL] [Abstract][Full Text] [Related]
19. Identification of HDAC4 as a potential therapeutic target and prognostic biomarker for ZFTA-fused ependymomas.
de Sousa GR; Salomão KB; Nagano LFP; Riemondy KA; Chagas PS; Veronez LC; Saggioro FP; Marie SKN; Yunes JA; Cardinalli IA; Brandalise SR; de Paula Queiroz RG; Scrideli CA; Donson AM; Foreman NK; Tone LG; Valera ET
Cancer Gene Ther; 2023 Aug; 30(8):1105-1113. PubMed ID: 37041276
[TBL] [Abstract][Full Text] [Related]
20. Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study.
Sasaki S; Takeda M; Hirose T; Fujii T; Itami H; Uchiyama T; Morita K; Matsuda R; Yamada S; Nakagawa I; Ohbayashi C
J Neuropathol Exp Neurol; 2022 Jan; 81(2):117-126. PubMed ID: 34897475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
